How much revenue does Immunotech Laboratories make?

Immunotech Laboratories reported $0 in revenue for fiscal year 2009.

What companies are similar to Immunotech Laboratories?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Verde Science, Inc. (VRCI), Poniard Pharmaceuticals, Inc. (PARD), NexImmune, Inc. (NEXI), Eureka 93 Inc. (LXLLF).

Immunotech Laboratories, Inc. (IMMB) Stock

About Immunotech Laboratories, Inc.

Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. Its flagship compound is ITV-1 (immune therapeutic vaccine), a suspension of irreversible pepsin fraction that is used in the treatment of HIV/AIDS and Hepatitis C, as well a...

At a glance

Immunotech Laboratories reported revenue of $0 for fiscal year 2009, and net income of -$977,570.

Figures from company filings; latest fiscal year ended December 31, 2009.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.